Stockwire.com: CHAT LIVE with other shareholders about: (OTCBB: ARGA), (OTCBB: AULO), (OTCBB: TCPS).
TMCnet - The World's Largest Communications and Technology Community
TMC Launches New Sites ::  NGC  |  4GWE  |  Green Tech  |  Satellite  |  IT |  ITEXPO  |  Healthcare  |  Smart Grid  |  M2M  |  Smart Products  |  AstriCon News  |  SATCON News
Share
TMCnews
[January 09, 2008]

Stockwire.com: CHAT LIVE with other shareholders about: (OTCBB: ARGA), (OTCBB: AULO), (OTCBB: TCPS).

(M2 PressWIRE Via Thomson Dialog NewsEdge)
RDATE:09012008

AUSTIN, TX -- Have you ever found yourself wondering what other
shareholders of your favorite stock were thinking?

Now you can by using the ONLY FREE LIVE CHAT available on the internet
dedicated to stock symbols.

Now you can by using Stockwire LIVE CHAT. Stockwire LIVE CHAT is the
only FREE chat room service on the internet with chat rooms dedicated
to stock symbols.

If you can't find a chat room for your favorite stock, just shoot us an
email at chat@stockwire.com requesting it and we will create it
immediately.

Stockwire LIVE CHAT is changing how investors interact with each other
and we are glad to be the ones bringing it to you FREE of charge!

Visit Stockwire.com and click the "Chat Live" button at the top to
begin chatting with your fellow shareholders!

----------------------------------------------------------

To enter the ARGA chat room, visit the following link:
http://www.stockwire.com/livechat

Auriga Laboratories, Inc. (OTCBB: ARGA) (Tue, January 8th, 2008, 8:45am
ET) Auriga Laboratories, Inc., a specialty pharmaceutical company,
announced today the signing of a co-promotion agreement with
MiddleBrook Pharmaceuticals, Inc., pursuant to which Auriga will
co-promote Keflex 750 mg capsules (cephalexin capsules, USP), to
Primary Care Specialists in the U.S.

Cephalexin, the generic form of Keflex, is the third most prescribed
outpatient antibiotic in the U.S., with approximately 25 million
prescriptions written annually. Cephalexin is the number-one most
prescribed oral cephalosporin antibiotic and is also the number-one
recommended oral antibiotic therapy for uncomplicated skin and skin
structure infections.

The co-promotion will begin during the 1st Quarter of 2008. "This
agreement solidifies Auriga's commitment to enhance our product
portfolio. Currently, over 50% of cephalexin prescriptions are written
by Primary Care Specialists which makes Keflex 750 mg a highly
synergistic addition to Auriga's current primary care promotional
efforts," said Philip S. Pesin, CEO of Auriga.

Aurelio Resource Corporation (OTCBB: AULO -
http://finance.yahoo.com/q?s=AULO.OB ) (Tue, January 8th, 2008, 6:00am
ET) Aurelio Resource Corporation is pleased to announce gold assay
results from recent drilling in the MAN Area of the Company's wholly
owned Hill Copper-Zinc Project, located in the Turquoise Mining
District, Cochise County, Arizona.

The fire assay results reported in Table 1 correspond to
previously-released copper, zinc, and silver assay information for
drill holes BR07-24 and -26 (see November 8, 2007 news release).

Drill hole BR07-25 was assayed for gold between the depths of 235 and
450 feet to determine the gold content of a previously-reported
copper/zinc/silver assay interval (175 feet at 1.45% copper, 0.45% zinc
and 1.8 parts-per-million (ppm) silver, including 100 ft averaging
2.29% copper, 0.11% zinc and 1.8 ppm silver). Gold assay results were
125 parts-per-billion (ppb) and 160 ppb, respectively, over these
intervals. The strongest gold intercept came below this interval, with
an average of 188 ppb between 410 feet and 450 feet.

Gold assays for holes BR07-27 and BR07-28 are pending.

The results indicate the presence of significant gold mineralization at
the MAN Area.

The Company's geologists believe that there are probably multiple
phases of gold deposition at the Hill project. Establishing the
distribution and nature of the gold mineralization will be a primary
focus of the next drilling program, scheduled for the first quarter of
2008.

----------------------------------------------------------

To enter the TCPS chat room, visit the following link:
http://www.stockwire.com/livechat

Terocelo, Inc. (OTCBB: TCPS) (Tue, January 8th, 2008, 11:14am ET)
Terocelo, Inc. previously announced it had entered into a Memorandum of
Understanding for the creation of a strategic alliance based on its
Lycon(tm) chip and proprietary True Software Radio(r) (TSR) with a
multibillion dollar Asian Technology fund. This transaction has not yet
closed, but critical hurdles have been cleared and the Company is to
meet with the fund's executives next week in what is believed to be a
final step toward consummation of the definitive agreement. The
definitive agreement will then be submitted for Board of Director and
shareholder approval.

Under the terms of the agreement, the fund will pay thirty million
dollars ($30,000,000) and continuing royalties to Terocelo in exchange
for certain exclusive license rights to the Company's TSR technology.
In addition, the fund will provide twenty million dollars ($20,000,000)
to establish and fund an independent corporate entity, in which
Terocelo will have an equity interest, to initiate Asian operations to
develop applications and promote the sales of products containing the
TSR technology. These funds will cover on-going costs for foundry
services, design center operations, application staging, as well as
marketing and sales efforts.

The ability to access these additional financial and human resources
should allow the Company to secure pending product development
contracts with industry leading corporations that are interested in
incorporating TSR technology into their product lines. Most
importantly, it will provide a solid financial base for the extended
future of Terocelo.

Prior to the completion of the Definitive Agreement, the Chinese
business group is in the process of delivering a series of bridge
financing instruments, which it is anticipated will provide sufficient
working capital to stabilize the Company's operations and allow its
engineering efforts to continue to develop the products for market.

----------------------------------------------------------

As a trader, a very intelligent place to put your money, is where the
money is flowing into. These are the kind of trades that you want to
get into.

As the saying goes...follow the money!

To see the complete Movers & Shakers Blog go to:
http://www.stockwire.com.

About Stockwire: Stockwire is a company that is pioneering a new way to
research companies before you invest them. It's called a Stockumentary.
A Stockumentary is a documentary on a publicly traded company. Imagine
a Dateline NBC segment, but on a publicly traded company. We are the
first company to ever bring this type of quality research to investors
in this format.

The Stockumentary has video interviews with management, product demos,
video tours of office or factory, research reports, sec filings and
much more. All of this is delivered to investors in high quality video,
either by mail or email.

Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is
an independent electronic publication committed to providing our
readers with factual information on selected publicly traded companies.

As detailed below, this publication accepts compensation from some of
the companies from which it features. To the degrees listed herein,
this Newsletter should not be regarded as an independent publication.
All statements and expressions are the sole opinions of the editors and
are subject to change without notice. A profile, description, or other
mention of a company in the Newsletter is neither an offer nor
solicitation to buy or sell any securities mentioned.

While we believe all sources of information to be factual and reliable,
in no way do we represent or guarantee the accuracy thereof, nor the
statements made herein.

We encourage our readers to invest carefully and read the investor
information available at the web sites of the Securities and Exchange
Commission ("SEC") at www.sec.gov and/or the National Association of
Securities Dealers ("NASD") at www.nasd.com. The NASD has published
information on how to invest carefully at its web site.

Readers can review all public filings by companies at the SEC's EDGAR
page. www.sec.gov/edgar.shtml

Stockwire.com is an independent electronic publication committed to
providing our readers with factual information on selected publicly
traded companies. Stockwire.com is not a registered investment advisor
or broker-dealer. All companies are chosen on the basis of certain
financial analysis and other pertinent criteria with a view toward
maximizing the upside potential for investors while minimizing the
downside risk, whenever possible.

From time to time SRGI sells shares in the open market it receives as
compensation for coverage of client companies. Since the shares are
received as compensation for services as previously disclosed, and not
for investment purposes, the editors do not view the sale of the shares
as contradictory to any advice delivered in the content. This should be
viewed as a conflict of interest by shareholders or prospective
shareholders of the client companies.

Moreover, as detailed below, this publication accepts compensation from
third party consultants and/or companies which it features on
Stockwire.com. Likewise, Stockwire.com is owned by Stockwire Research
Group Inc. (SRGI). To the degrees enumerated herein, this newsletter
and website should not be regarded as an independent publication.

All statements and expressions are the sole opinions of the editors and
are subject to change without notice. A profile, description, or other
mention of a company on Stockwire.com is neither an offer nor
solicitation to buy or sell any securities mentioned. While we believe
all sources of information to be factual and reliable, in no way do we
represent or guarantee the accuracy thereof, nor the statements made
herein.

The editor, members of the editor's family, and/or entities with which
the editor is affiliated aside from Stockwire Research Group Inc.
(SRGI) itself, are forbidden by company policy to own, buy, sell or
otherwise trade stock for their own benefit in the companies who appear
in the publication unless specifically disclosed in the newsletter.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE
BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES
IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND
IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES
AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED,
WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.

We often accept restricted shares of company stock; by SEC regulations,
restricted shares cannot be sold into the market for a period of at
least one year from the time that the shares are issued. In such cases,
we detail in the Disclaimer the specific term of any restrictions. We
also receive compensation in the form of stock options, in which case
we receive the right to buy shares of the stock of the company at
issue, at a specified time and a specified price. In such
circumstances, we specify on our Disclaimer the terms of the options
received. On occasion, we also accept free-trading shares in a company
that we cover. However, by policy we generally do not buy or sell any
shares of a company's stock within three trading days after any such
company's profile, commentary, or other company-specific information is
disseminated on Stockwire.com Web site. In cases where we do trade
within the three day window, our volume will never represent more than
5% of the daily volume, thereby minimizing any effect we could have on
the potential price movement.

While our policies as detailed above are designed to minimize any
impact upon our members of a conflict of interest between our company
and our members, each member should be fully aware that such potential
and actual conflicts of interest may well exist due to the compensation
structure detailed herein. For this reason, and because the information
contained on Stockwire.com is updated on a regular basis as
circumstances change, each member is strongly encouraged to
periodically review the Profile Compensation section at
http://www.stockwire.com/disclaimer_profiles.htm.

CONTACT: The Stockwire Group
Tel: +1 512 358 8440
e-mail: info@stockwire.com

((M2 Communications Ltd disclaims all liability for information
provided within M2 PressWIRE. Data supplied by named party/parties.
Further information on M2 PressWIRE can be obtained at
http://www.presswire.net on the world wide web. Inquiries to
info@m2.com)).

Copyright 2008 M2 Communications Ltd.

[ Back To TMCnet.com's Homepage ]


Discussions:
Be the first to post a comment on this page!
 
By  
TMCnet
Featured White Papers
Top Stories
Related VoIP News

Subscribe FREE to all of TMC's monthly magazines. Click here now.